Jack Allen
Stock Analyst at Robert W. Baird
(0.04)
# 4,804
Out of 5,081 analysts
335
Total ratings
28%
Success rate
-17.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KARD Kardigan | Initiated Coverage: Buy | $43 | $12.80 | +235.94% | 1 | Oct 21, 2026 | |
| CLLS Cellectis | Reiterated: Buy | $10 → $8 | $0.98 | +716.33% | 27 | Sep 15, 2026 | |
| RARE Ultragenyx Pharmaceutical | Downgraded: Hold | $40 → $16 | $15.65 | +2.24% | 13 | Sep 3, 2026 | |
| TSHA Taysha Gene Therapies | Reiterated: Buy | $12 → $15 | $3.96 | +278.79% | 27 | Jun 30, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $57 | $17.08 | +233.72% | 1 | Jun 26, 2026 | |
| LYEL Lyell Immunopharma | Initiated Coverage: Buy | $49 | $9.39 | +421.83% | 1 | May 1, 2026 | |
| NTLA Intellia Therapeutics | Reiterated: Hold | $7 → $13 | $11.21 | +15.97% | 25 | Apr 27, 2026 | |
| ALLO Allogene Therapeutics | Reiterated: Buy | $7 → $9 | $1.25 | +620.00% | 23 | Apr 14, 2026 | |
| TIL Instil Bio | Downgraded: Hold | $180 → $7 | $5.84 | +19.86% | 28 | Jan 7, 2026 | |
| MREO Mereo BioPharma Group | Reiterated: Buy | $8 → $1 | $0.2817 | +254.99% | 5 | Dec 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $64 → $46 | $18.26 | +151.92% | 29 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $52 → $44 | $49.39 | -10.91% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.00 | n/a | 20 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $6 | $2.40 | n/a | 9 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $1.74 | n/a | 27 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 → $4 | $2.11 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0002 | n/a | 14 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $10.71 | n/a | 17 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $84 | $30.98 | n/a | 9 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $72 → $65 | $55.95 | n/a | 9 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $27 | $8.65 | n/a | 17 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $200 → $25 | $11.98 | n/a | 9 | Sep 26, 2023 |
Kardigan
Oct 21, 2026
Initiated Coverage: Buy
Price Target: $43
Current: $12.80
Upside: +235.94%
Cellectis
Sep 15, 2026
Reiterated: Buy
Price Target: $10 → $8
Current: $0.98
Upside: +716.33%
Ultragenyx Pharmaceutical
Sep 3, 2026
Downgraded: Hold
Price Target: $40 → $16
Current: $15.65
Upside: +2.24%
Taysha Gene Therapies
Jun 30, 2026
Reiterated: Buy
Price Target: $12 → $15
Current: $3.96
Upside: +278.79%
Faeth Therapeutics
Jun 26, 2026
Initiated Coverage: Buy
Price Target: $57
Current: $17.08
Upside: +233.72%
Lyell Immunopharma
May 1, 2026
Initiated Coverage: Buy
Price Target: $49
Current: $9.39
Upside: +421.83%
Intellia Therapeutics
Apr 27, 2026
Reiterated: Hold
Price Target: $7 → $13
Current: $11.21
Upside: +15.97%
Allogene Therapeutics
Apr 14, 2026
Reiterated: Buy
Price Target: $7 → $9
Current: $1.25
Upside: +620.00%
Instil Bio
Jan 7, 2026
Downgraded: Hold
Price Target: $180 → $7
Current: $5.84
Upside: +19.86%
Mereo BioPharma Group
Dec 29, 2025
Reiterated: Buy
Price Target: $8 → $1
Current: $0.2817
Upside: +254.99%
Dec 23, 2025
Reiterated: Buy
Price Target: $64 → $46
Current: $18.26
Upside: +151.92%
Nov 11, 2025
Reiterated: Hold
Price Target: $52 → $44
Current: $49.39
Upside: -10.91%
Sep 23, 2025
Reiterated: Buy
Price Target: $5
Current: $1.00
Upside: n/a
Aug 13, 2025
Reiterated: Buy
Price Target: $10 → $6
Current: $2.40
Upside: n/a
Jul 17, 2025
Reiterated: Buy
Price Target: $18
Current: $1.74
Upside: n/a
May 14, 2025
Reiterated: Hold
Price Target: $5 → $4
Current: $2.11
Upside: n/a
May 12, 2025
Rated: Hold
Price Target: n/a
Current: $0.0002
Upside: n/a
May 12, 2025
Rated: Hold
Price Target: n/a
Current: $10.71
Upside: n/a
Nov 6, 2024
Reiterated: Buy
Price Target: $84
Current: $30.98
Upside: n/a
Oct 30, 2024
Reiterated: Hold
Price Target: $72 → $65
Current: $55.95
Upside: n/a
Nov 16, 2023
Reiterated: Hold
Price Target: $27
Current: $8.65
Upside: n/a
Sep 26, 2023
Downgraded: Hold
Price Target: $200 → $25
Current: $11.98
Upside: n/a